烯丙基L-丙氨酸酯 | 44812-81-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 烯丙基L-丙氨酸酯
• 中文别名: L-丙氨酸烯丙基酯4-甲苯磺酸盐
• 英文名称: L-alanine allyl ester
• 英文别名: Ala(O-allyl)；H-Ala-OAll；(S)-Allyl 2-aminopropanoate；prop-2-enyl (2S)-2-aminopropanoate
• CAS: 44812-81-9
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: LJNLJIGRKBHXCT-YFKPBYRVSA-N

物化性质

• 沸点：
  162.8±15.0 °C(Predicted)
• 密度：
  0.991±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  烯丙基L-丙氨酸酯 在 乙酸铵 、 sodium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 反应 15.0h， 生成 2-Propenyl 2-[5-(4-bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-3-propanoate
  参考文献：
  名称：

  Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1

  摘要：

  A series of inhibitors for anti-apoptotic Bcl-2 proteins based on BHI-1 were synthesized and their binding interactions with Bcl-2. Bcl-X-L, and Bcl-w were evaluated. It was found that modification of BHI-1 resulted in varied binding profiles among Bcl-2, Bcl-XL, and Bcl-w, and a set of inhibitors with varied selectivity to Bcl-2, Bcl-X-L, and Bcl-w proteins have been identified. Molecular modeling of the interaction of the BHI-1 based analogues with the anti-apoptotic Bcl-2 proteins suggested that the binding site for the BHI-1 based inhibitor was the least conserved section among Bcl-2, Bcl-X-L, and Bcl-w: targeting the non-conserved section may account for the observed selectivity of the BHI-1 based inhibitors among the anti-apoptotic Bcl-2 proteins. The validity of the model was supported by a strong correlation between the model-calculated binding energy and the experimental binding affinity. In summary, our studies suggest that most of the reported inhibitors for anti-apoptotic Bcl-2 proteins are nonselective and BHI-1 is a promising template to distinguish among Bcl-2, Bcl-X-L, and Bcl-w by targeting the non-conserved domain among the anti-apoptotic Bcl-2 proteins. Molecular-modeling-aided rational development of BHI-1 based selective inhibitor for antiapoptotic Bcl-2 proteins is underway. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2006.12.020
• 作为产物：
  描述：

  Boc-Ala-OAll 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以95%的产率得到烯丙基L-丙氨酸酯
  参考文献：
  名称：

  通过侧链锚固策略固相合成肽硒酸酯

  摘要：

  肽硒酸酯最近已经成为大型多肽和蛋白质基于连接的组装的关键组成部分。在本文中，我们报告了一种高效的固相方法，可使用侧链固定化策略进行肽硒酸酯的高产率和无差向异构化合成。

  DOI：

  10.1039/c7cc00823f

文献信息

• [EN] LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT<br/>[FR] FRAGMENT DE LACTOFERRINE DESTINÉ À ÊTRE UTILISÉ EN TANT QU'AGENT ANTIBACTÉRIEN ET ANTIVIRAL
  申请人：FARMAGENS HEALTH CARE SRL

  公开号：WO2017025846A1

  公开（公告）日：2017-02-16

  New peptide fragments of bovine lactoferrin having antimicrobial and antiviral activity, and derivatives thereof, used as active principle in antimicrobial and antiviral agents and compositions.

  牛乳铁蛋白的新型肽片段具有抗微生物和抗病毒活性，以及其衍生物，用作抗微生物和抗病毒剂和组合物中的活性成分。
• The tetrabenzylglucosyloxycarbonyl(BGloc)-group-A carbohydrate-derived enzyme-labile urethane protecting group
  作者：Thomas Kappes、Herbert Waldmann

  DOI：10.1016/s0008-6215(97)00224-3

  日期：1997.12

  Abstract The development of the tetrabenzylglucosyloxycarbonyl (BGloc)-protecting group as an enzymatically removable urethane protecting function for peptide synthesis is described. BGloc-protected amino acids are readily synthesized by conversion of amino acid allyl esters into the respective isocyanates, subsequent treatment with 2,3,4,6-tetrabenzylglucose and C -terminal allyl ester cleavage. From

  摘要描述了四苄基葡糖氧基氧羰基（BGloc）保护基作为肽合成中可酶解的氨基甲酸酯保护功能的发展。通过将氨基酸烯丙基酯转化成相应的异氰酸酯，随后用2,3,4,6-四苄基葡萄糖和C末端烯丙基酯裂解进行处理，可以容易地合成BGloc保护的氨基酸。从BGloc掩蔽的二肽酯（可通过肽化学的标准方法获得），通过氢化除去苄基醚，然后通过α-和β-水解氨基甲酸酯，以高收率选择性地裂解N末端氨基甲酸酯。葡萄糖苷酶在非常温和的反应条件下。
• [EN] PHOSPHORAMIDATE NUCLEOSIDE PRODRUG FOR TREATING VIRAL DISEASES AND CANCER, PROCESSES FOR THEIR PREPARATION AND THEIR USE<br/>[FR] PROMÉDICAMENT NUCLÉOSIDE PHOSPHORAMIDATE DESTINÉ AU TRAITEMENT DES MALADIES VIRALES ET DU CANCER, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION
  申请人：IVACHTCHENKO ALEXANDRE VASILIEVICH

  公开号：WO2018022221A1

  公开（公告）日：2018-02-01

  The present invention pertains to chemotherapeutic agents and their use for treating viral and cancerous diseases. These compounds are inhibitors of HCV NS5B polymerase, HBV DNA polymerase and, HIV-1 reverse transcriptase (RT) inhibitor, and for treatment of hepatitis B and C infection in mammals. These compounds are also of interest for the treatment of cancer. The phosphoramidate nucleoside prodrug of the general formula (1), a stereoisomer, isotope-enriched analogue, pharmaceutically acceptable salt, hydrate, solvate, or crystalline or polymorphic form thereof, formula (1) wherein: Ar is aryl or hetaryl; R1 is H or CH3, R2 is the substituent selected from OCH2CH=CH2, OCH2CH≡CH, OCH2CH2CH2OCH3, formula (2), formula (3) or formula (4), R3 is H or CH3; R4 is OH, OR5, NR6R7; R5 is C1-C4-alkyl; R6 and R7 are not necessarily the same substituents selected from H or CH3, Z = O, or NH; an arrow (→) indicates the place of substituent connection; Nuc is formula (5) or (6); R8 and R9 are not necessarily the same substituents selected from H, F, Cl, CH3 or OH provided when continuous line and its accompanying dotted line ( ) together are the single carbon-carbon (C-C) bond or R8 and R9 are hydrogen provided when continuous line and its accompanying dotted line ( ) together are the double carbon-carbon bond (C=C); R10 is the substituent selected from R10.1- R10.5; R10.1 R10.2 R10.4 R10.5 ; R11 is the substituent selected from H, F, CI, CH3, or CF3; R12 is hydrogen, C1-C4-alkyl or C3-C6-cycloalkyl; X is oxygen or ethanediyl-1,1 (C=CH2); Y is O, S, CH2, or HO-CH group provided when continuous line and its accompanying dotted line (formula 7) together are the single carbon-carbon (C-C) bond or Y is CH group provided when continuous line and its accompanying dotted line (formula 7) together are the double carbon-carbon bond (C=C), and compound of the general formula (1), stereoisomers, isotope-enriched analogues, pharmaceutically acceptable salts, hydrates, solvates, or crystalline or polymorphic forms thereof, wherein: Ar is aryl or hetaryl; R1 is H or CH3; R2 is isopropyl; Nuc is formula (8), (9) or (10).

  本发明涉及化疗药物及其用于治疗病毒性和癌症疾病的用途。这些化合物是HCV NS5B聚合酶、HBV DNA聚合酶和HIV-1逆转录酶（RT）抑制剂，用于治疗哺乳动物中的乙型和丙型肝炎感染。这些化合物也对癌症治疗具有兴趣。通用式（1）的磷酰胺核苷前药的立体异构体、同位素富集类似物、药学上可接受的盐、水合物、溶剂合物或晶体或多形式，式（1）其中：Ar为芳基或杂芳基；R1为H或CH3，R2为从O CH=CH2、O CH≡CH、O O 、式（2）、式（3）或式（4）中选择的取代基，R3为H或 ；R4为OH、OR5、NR6R7；R5为C1-C4-烷基；R6和R7不一定相同，选择自H或 的取代基，Z=O或NH；箭头（→）表示取代基连接的位置；Nuc为式（5）或（6）；R8和R9不一定相同，选择自H、F、Cl、 或OH，提供当连续线及其相应的虚线（）一起为单碳-碳（C-C）键时，或R8和R9为氢，提供当连续线及其相应的虚线（）一起为双碳-碳键（C=C）时；R10为从R10.1-R10.5中选择的取代基；R10.1 R10.2 R10.4 R10.5；R11为从H、F、Cl、 或CF3中选择的取代基；R12为氢、C1-C4-烷基或C3-C6-环烷基；X为氧或乙烯二基-1,1（C= ）；Y为O、S、 或HO-CH基，提供当连续线及其相应的虚线（式7）一起为单碳-碳（C-C）键时，或Y为CH基，提供当连续线及其相应的虚线（式7）一起为双碳-碳键（C=C）时，以及通用式（1）的化合物、立体异构体、同位素富集类似物、药学上可接受的盐、水合物、溶剂合物或晶体或多形式，其中：Ar为芳基或杂芳基；R1为H或 ；R2为异丙基；Nuc为式（8）、（9）或（10）。
• The use of penicillin acylase for selective N-terminal deprotection in peptide synthesis
  作者：Herbert Waldmann

  DOI：10.1016/s0040-4039(00)86668-x

  日期：1988.1

  Penicillin acylase from E. coli (EC 3.5.1.11) accepts a broad range of N-phenylacetyl-dipeptide esters as substrates. The enzyme hydrolyses the N-terminal protecting group selectively at room temp. and pH=8.1 without affecting the peptide- or the ester-bonds. Alternatively methyl-, benzyl-, tert-butyl and allyl esters can be cleaved chemically leaving the phenylacetamido moiety intact.

  来自大肠杆菌的青霉素酰基转移酶（EC 3.5.1.11）接受各种N-苯基乙酰基-二肽酯作为底物。该酶在室温下选择性水解N末端保护基。pH = 8.1，且不影响肽键或酯键。或者，可以化学裂解甲基，苄基，叔丁基和烯丙基酯，而使苯基乙酰胺基部分完整。
• [EN] ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS<br/>[FR] DÉRIVÉS D'ACIDE ARYLSULFONYLAMINOMÉTHYLPHOSPHONIQUE, PRÉPARATION DE CEUX-CI ET UTILISATION DE CEUX-CI COMME COMPOSITIONS PHARMACEUTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009030715A1

  公开（公告）日：2009-03-12

  The invention relates tosubstitutedarylsulphonylaminomethylphosphonic acid derivativesof general formula (I) wherein the groups Ra to Rf, A and Z are defined as mentioned in the specification and claims, which are suitable for preparinga medicament for the treatmentof metabolic disorders, particularlytype 1 or type 2 diabetesmellitus.

  该发明涉及通式（I）的取代芳基磺胺甲基膦酸衍生物，其中基团Ra至Rf、A和Z的定义如规范和权利要求中所述，适用于制备用于治疗代谢紊乱，特别是1型或2型糖尿病的药物。